Ortho-ATI shows promise in hip tendon pain
16 June, 2014 by Dylan Bushell-EmblingOrthocell has presented results of a successful pilot trial of regenerative therapy Ortho-ATI in 12 patients with gluteal tendinopathy.
GI Dynamics presents EndoBarrier research
16 June, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has presented more research into the effectiveness of - and mechanism of action behind - EndoBarrier, its non-surgical device therapy for obesity and type 2 diabetes.
Starpharma completes chairman succession
16 June, 2014 by Dylan Bushell-EmblingRob Thomas has formally taken over from Peter Bartels as chairman of Starpharma (ASX:SPL) following a seven-month transition period.
AsureQuality receives certification for medical device
16 June, 2014AsureQuality has recieved certification for the contract manufacture of in vitro diagnostic medical devices.
Phosphagenics employees plead guilty over fraud
13 June, 2014A hearing into the alleged fraud against Phosphagenics has resulted in two men pleading guilty to issuing false invoices worth millions of dollars.
Biotech survey shows advanced manufacturing heading overseas
12 June, 2014The annual Biotechnology Industry Position Survey (2014) shows a worrying trend: advanced manufacturing associated with this industry of the future is following traditional manufacturing and there has been a sharp increase in the number of companies heading overseas.
UWA Professor named WA's Chief Scientist
11 June, 2014 by Dylan Bushell-EmblingMedical research luminary Professor Peter Klinken has taken the role of Western Australia's Chief Scientist and aims to change the state's research focus from oil and gas mining to biotechnology.
Outcome on employee share schemes expected mid-June
10 June, 2014Treasury has confirmed that issues raised in submissions to its review of 'employee share schemes (ESS) and start-ups' will be considered by the Prime Minister's taskforce established to develop a National Industry Investment and Competitiveness Agenda, which is expected to be delivered in the coming weeks.
First burns patient treated in NovoSorb BTM trial
06 June, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) revealed that the first burns patient enrolled in a clinical trial of its NovoSorb BTM has been successfully treated and is out of intensive care.
Starpharma making progress with clinical trials
06 June, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has dosed the first group of patients for a phase I trial of DEP docetaxel in solid tumours and commenced final preparations for a phase III trial of VivaGel for the prevention of BV recurrence.
New guidance for ASX-listed companies
05 June, 2014Two new guidance documents are now available to support ASX-listed companies. The third edition of the ASX's Corporate Governance Principles and Recommendations (CGPR) comes into effect on 1 July after a recent review, and ASIC has released guidance to ASX-listed entities on analyst and investor briefings.
ResMed wins import ban against Taiwan's APEX
05 June, 2014 by Dylan Bushell-EmblingAn ITC judge has ruled that two products from Taiwanese manufacturer APEX still infringe on ResMed (ASX:RMD) patents and cannot be imported or sold in the US.
AusMedtech responds to the TGA's review of the low value turnover exemption scheme
03 June, 2014AusMedtech has told the TGA's review that it is concerned that only a very low number of small businesses are taking advantage of the low value turnover exemption (LVT) scheme, despite the eligibility of their products.
Cochlear to launch new implant in EU in June
02 June, 2014 by Dylan Bushell-EmblingCochlear (ASX:COH) will this month launch the first in its Nucleus Profile line of implants - the successor to its Cl500 series - in Europe.
Benitec treats first patient in HCV trial
02 June, 2014 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has commenced a phase I/IIa trial of ddRNAi-based therapeutic TT-034, marking the first time the treatment candidate has been used in humans.
